144 related articles for article (PubMed ID: 10854153)
1. B7-1 gene-modified autologous tumor-cell vaccines for renal-cell carcinoma.
Antonia SJ; Seigne JD
World J Urol; 2000 Apr; 18(2):157-63. PubMed ID: 10854153
[TBL] [Abstract][Full Text] [Related]
2. Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7-1 (CD8O) costimulation.
Wang YC; Zhu L; McHugh R; Graham SD; Hillyer CD; Dillehay D; Sell KW; Selvaraj P
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):1-8. PubMed ID: 9147700
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma.
Antonia SJ; Seigne J; Diaz J; Muro-Cacho C; Extermann M; Farmelo MJ; Friberg M; Alsarraj M; Mahany JJ; Pow-Sang J; Cantor A; Janssen W
J Urol; 2002 May; 167(5):1995-2000. PubMed ID: 11956426
[TBL] [Abstract][Full Text] [Related]
4. Gene transfer of the Co-stimulatory molecules B7-1 and B7-2 enhances the immunogenicity of human renal cell carcinoma to a different extent.
Jung D; Hilmes C; Knuth A; Jaeger E; Huber C; Seliger B
Scand J Immunol; 1999 Sep; 50(3):242-9. PubMed ID: 10447932
[TBL] [Abstract][Full Text] [Related]
5. Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells.
Meijer SL; Dols A; Urba WJ; Hu HM; Smith II JW; Vetto J; Wood W; Doran T; Chu Y; Sayaharuban P; Alvord WG; Fox BA
J Immunother; 2002; 25(4):359-72. PubMed ID: 12142559
[TBL] [Abstract][Full Text] [Related]
6. Antigen loss variants of a murine renal cell carcinoma: implications for tumor vaccination.
Kerkmann-Tucek A; Banat GA; Cochlovius B; Zöller M
Int J Cancer; 1998 Jul; 77(1):114-22. PubMed ID: 9639402
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma.
Mulders P; Tso CL; Pang S; Kaboo R; McBride WH; Hinkel A; Gitlitz B; Dannull J; Figlin R; Belldegrun A
J Immunother; 1998 May; 21(3):170-80. PubMed ID: 9610908
[TBL] [Abstract][Full Text] [Related]
8. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
9. Prevention of hepatocellular carcinoma in mice by IL-2 and B7-1 genes co-transfected liver cancer cell vaccines.
Ge NL; Ye SL; Zheng N; Sun RX; Liu YK; Tang ZY
World J Gastroenterol; 2003 Oct; 9(10):2182-5. PubMed ID: 14562374
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
[TBL] [Abstract][Full Text] [Related]
11. Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines.
Belldegrun A; Tso CL; Sakata T; Duckett T; Brunda MJ; Barsky SH; Chai J; Kaboo R; Lavey RS; McBride WH
J Natl Cancer Inst; 1993 Feb; 85(3):207-16. PubMed ID: 8423625
[TBL] [Abstract][Full Text] [Related]
12. Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse.
Schendel DJ; Frankenberger B; Jantzer P; Cayeux S; Nöbetaner E; Willimsky G; Maget B; Pohla H; Blankenstein T
Gene Ther; 2000 Dec; 7(23):2007-14. PubMed ID: 11175312
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma.
Fishman M; Hunter TB; Soliman H; Thompson P; Dunn M; Smilee R; Farmelo MJ; Noyes DR; Mahany JJ; Lee JH; Cantor A; Messina J; Seigne J; Pow-Sang J; Janssen W; Antonia SJ
J Immunother; 2008 Jan; 31(1):72-80. PubMed ID: 18157014
[TBL] [Abstract][Full Text] [Related]
14. Tumor cell-based vaccination in renal cell carcinoma: rationale. approaches, and recent clinical development.
Volk J; Sel S; Ganser A; Schöffski P
Curr Drug Targets; 2002 Oct; 3(5):401-8. PubMed ID: 12182231
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor effect of murine renal cell carcinoma cells genetically modified to express B7-1 combined with cytokine secreting fibroblasts.
Wang J; Nakamoto T; Kasaoka Y; Usui T; Hamada H
Hiroshima J Med Sci; 2000 Mar; 49(1):73-82. PubMed ID: 10824460
[TBL] [Abstract][Full Text] [Related]
16. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer.
Wysocki PJ; Kazimierczak U; Suchorska W; Kotlarski M; Malicki J; Mackiewicz A
Cancer Gene Ther; 2010 Jul; 17(7):465-75. PubMed ID: 20168352
[TBL] [Abstract][Full Text] [Related]
17. Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine.
Zhou X; Jun DY; Thomas AM; Huang X; Huang LQ; Mautner J; Mo W; Robbins PF; Pardoll DM; Jaffee EM
Cancer Res; 2005 Feb; 65(3):1079-88. PubMed ID: 15705910
[TBL] [Abstract][Full Text] [Related]
18. Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs.
Frankenberger B; Pohla H; Noessner E; Willimsky G; Papier B; Pezzutto A; Kopp J; Oberneder R; Blankenstein T; Schendel DJ
Clin Cancer Res; 2005 Mar; 11(5):1733-42. PubMed ID: 15755994
[TBL] [Abstract][Full Text] [Related]
19. B7-1 gene transfer into human cancer cells by infection with an adenovirus-B7 (Ad-B7) expression vector.
Dessureault S; Graham F; Gallinger S
Ann Surg Oncol; 1996 May; 3(3):317-24. PubMed ID: 8726189
[TBL] [Abstract][Full Text] [Related]
20. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]